Tarsus Pharmaceuticals (TARS) has drawn fresh attention after dosing the first participant in its Phase 2 Calliope trial of TP-05, an oral candidate aimed at preventing Lyme disease by killing infected ticks.

The recent TP-05 progress and TP-03 milestone in China come as the share price sits at US$70.22, with a 7 day share price return of 4.9% but a 90 day share price return showing a 14.2% decline. The 1 year total shareholder return of 36.4% and very large 3 year total shareholder return highlight how momentum has cooled after a very strong multi year run.

If you are looking beyond a single biotech story, this could be a good moment to broaden your watchlist with 33 healthcare AI stocks

With a commercial eye care product, growing revenue and a loss making income line, plus a share price well off its recent highs yet still far above where it was three years ago, is Tarsus now a potential opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 19.7% Undervalued

At a last close of $70.22 versus a narrative fair value of $87.50, the most followed view sees meaningful upside already built into the story.

Expanded market access and international regulatory initiatives support top line growth, margin stability, and greater long term global revenue diversification. Strong demand from patient awareness and favorable demographic trends drive sustainable revenue expansion and reduce concentration risk through multi product pipeline development.

Want to see what sits behind that confidence in higher margins and a bigger revenue base? The narrative leans heavily on future earnings power and a richer profit profile. Curious which growth, margin and valuation assumptions have to line up for $87.50 to make sense.

Result: Fair Value of $87.50 (UNDERVALUED)

However, this depends on XDEMVY maintaining strong uptake, while high SG&A and revenue concentration risk do not erode the path to those healthier margins.

Another View: What The Sales Multiple Is Telling You

While the narrative fair value points to meaningful upside, the current P/S ratio of 6.6x paints a more cautious picture. It is richer than the US pharmaceuticals industry average of 4.6x, yet below the peer average of 16.1x and close to a fair ratio of 6.9x, which suggests less obvious mispricing and more balanced risk. So the key question is whether the tension lies between growth expectations and what you are willing to pay for every dollar of revenue.

Next Steps

Mixed signals so far, with both risks and rewards in focus. Check the data now and weigh up the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with just one stock here, you could miss other opportunities that fit your style. Use the screener to actively stack your watchlist with ideas.

• Target quality at a discount by scanning for companies flagged in the 63 high quality undervalued stocks that match your return and risk preferences.
• Prioritise resilience by searching for companies in the 65 resilient stocks with low risk scores that align with a steadier approach to compounding capital.
• Spot early potential by checking the screener containing 25 high quality undiscovered gems for businesses with solid fundamentals that are not yet widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.